Detail of the clinical trial
| Title of the trial | A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non-Hodgkin Lymphoma (iNHL) |
|---|---|
| EudraCT number | 2019-001381-14 |
| Protocol number | VS-0145-229 |
| Sponsor | Secura Bio, Inc., 1195 Village Center cir, Suite 128, Las Vegas, NV 89134, United States of America |
| Indications | Hemato-oncology |
| Diagnosis | Non-Hodgkin Lymphoma |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2019 |
| Date of approval by Institute (SÚKL) | 31.10.2019 |
| Date of approval by EC | 4.9.2019 |
| Date of initiation CT in ČR | 8.7.2020 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
Fakultní nemocnice Hradec Králové,IV. interní hematologická klinika,Sokolská 581,Hradec Králové,500 05 Fakultní nemocnice Ostrava,Klinika hematoonkologie,17. listopadu 1790/5,Ostrava-Poruba,708 52 Všeobecná fakultní nemocnice v Praze,I. Interní klinika - Klinika hematologie VFN a 1.LF UK v Praze,U Nemocnice 2,Praha 2,128 08 |
cz